Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Protalix BioTherapeutics
Protalix BioTherapeutics
Chiesi Fabry disease treatment gets EU marketing authorization
Labiotech.eu
Wed, 05/10/23 - 10:06 am
Chiesi
Protalix BioTherapeutics
Europe
Fabry disease
PRX-102
Protalix eyes Fabry drug resubmission thanks to multiple phase 3 readouts
Fierce Biotech
Sun, 03/20/22 - 11:05 pm
Protalix BioTherapeutics
Fabry disease
FDA
clinical trials
PRX-102
Protalix to propose virtual inspection to clear barrier to FDA approval
Biopharma Reporter
Thu, 05/20/21 - 11:10 am
Protalix BioTherapeutics
Chiesi Farmaceutica
Fabry disease
FDA
Protalix's Fabry Disease Treatment Hits the Mark in Phase III Switch-Over Study
BioSpace
Thu, 12/31/20 - 12:01 pm
Protalix BioTherapeutics
PRX-102
clinical trials
Fabry disease
Biotech Protalix, Chiesi edge close to potential Fabry disease approval
Fierce Biotech
Thu, 05/28/20 - 10:53 am
Protalix BioTherapeutics
Chiesi
Fabry disease
pegunigalsidase alfa
Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash
Fierce Biotech
Tue, 10/13/15 - 12:16 pm
Protalix BioTherapeutics
Pfizer
R&D
Gaucher disease
Elelyso
3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology
Yahoo/Benzinga
Mon, 08/25/14 - 08:25 am
genetic engineering
plantibodies
antibodies
iBio
PlantForm
Protalix BioTherapeutics
Protalix Drug in Phase IIa Study for Gaucher Disease
Yahoo/Zacks.com
Fri, 06/20/14 - 11:02 am
Protalix BioTherapeutics
Gaucher disease
PRX-112
Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
Yahoo/Globe Newswire
Wed, 06/18/14 - 09:45 am
PRX-112
Protalix BioTherapeutics
Gaucher disease
Eight Biotech Stocks Trading Near $5 With Huge Upside Potential
24/7 Wall St
Fri, 02/7/14 - 09:43 am
Array Biopharma
Biodel
Galena Biopharma
Novavax
Protalix BioTherapeutics
Rigel Pharmaceuticals
Synta Pharmaceuticals
Zogenix
Pulse of J.P. Morgan 2014: Interviews with 17 biopharma execs
Fierce Biotech
Fri, 01/17/14 - 05:54 pm
JPMHC 2014
Algeta
Macrogenics
Xencor
Acetylon
Enanta Pharmaceuticals
Clinigen
Iroko Pharmaceuticals
Protalix BioTherapeutics
Ambrx
Roche
Sialix
Verastem
pRED
Cubist Pharmaceuticals
Celgene
Otonomy
Lumena Pharmaceuticals
Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More
24/7 Wall St
Tue, 01/7/14 - 11:47 am
Celldex Therapeutics
Immunomedics
Keryx
Merrimack Pharmaceuticals
Protalix BioTherapeutics
Can Protalix Revolutionize This Orphan Disease?
Motley Fool
Tue, 10/15/13 - 05:01 pm
orphan drugs
Protalix BioTherapeutics
Gaucher disease
Vpriv
Shire
Sanofi
Genzyme
Cerezyme
Elelyso
Should You Buy Protalix for Its Platform Alone?
Motley Fool
Sun, 09/22/13 - 11:37 am
Protalix BioTherapeutics
ProCellEx
How Far Can $69 Million Take Protalix?
Motley Fool
Thu, 09/19/13 - 03:32 am
Protalix BioTherapeutics
3 Ways Big Pharma Is Seizing This Rare Opportunity
Motley Fool
Fri, 04/5/13 - 10:21 am
Merck
Endocyte
Eli Lilly
Pfizer
Repligen
AbbVie
Protalix BioTherapeutics
This Week in Biotech
Motley Fool
Sun, 02/10/13 - 11:27 am
Hyperion Therapeutics
Celgene Corporation
ONYX Pharmaceuticals
Oncolytics
Biogen Idec
Protalix BioTherapeutics
Pfizer
Protalix extends collaboration on Gaucher disease drug; Pfizer will manage new Elelyso trials
Yahoo/AP
Fri, 12/7/12 - 10:38 am
Protalix BioTherapeutics
Pfizer
Gaucher disease
Elelyso
Protalix Biotherapeutics: Eyes On Elelyso Sales And Advancing Pipeline
Seeking Alpha
Mon, 10/1/12 - 11:28 am
Protalix BioTherapeutics
Elelyso
Pfizer
Sanofi
Shire
ProCellEx
A Home Run Drug in the Holy Land
Motley Fool
Sat, 09/29/12 - 11:48 am
Elelyso
Gaucher disease
Protalix BioTherapeutics
Pages
1
2
3
4
next ›
last »